Skip to main content

Table 3 Efficacy comparison of different first-line treatments based on a tumour assessment

From: Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

Tumour assessment

First-line treatment

P value

1-CRZ(n = 32)

1-PP(n = 28)

N1-PP(n = 13)

Type of response, n %

    

 Complete response

1 (3.1)

0 (0)

0 (0)

 

 Partial response

24 (75.0)

5 (17.9)

2 (15.4)

 

 Stable disease

7 (21.9)

11 (39.3)

4 (30.8)

 

 Progressive disease

0 (0)

9 (32.1)

6 (46.1)

 

 Not evaluable

0 (0)

3 (10.7)

1 (7.7)

 

 ORR(%)

78.1

17.9

15.4

<0.001

 DCR(%)

100.0

57.2

46.2

<0.001

  1. Note. — Unless otherwise indicated, the data are shown as numbers with percentages in parentheses. The statistical analysis for DCR and ORR were performed using the Chi-Square test